

1 ADVANCES IN THE MEDICAL MANAGEMENT OF BOWEL ENDOMETRIOSIS

2

3 Paolo Vercellini, M.D.^{a,b}

4 Greta Sergenti, M.D.^a

5 Laura Buggio, M.D.^b

6 Maria Pina Frattaruolo, M.D.^b

7 Dhouha Dridi, M.D.^{a,b}

8 Nicola Berlanda, M.D.^b

9

10 From the ^aDepartment of Clinical Sciences and Community Health, Università degli Studi and

11 ^bFondazione Ca' Granda Ospedale Maggiore Policlinico, Via Commenda, 12 - 20122 Milan, Italy

12

13

14 Correspondence:

15 Paolo Vercellini, M.D.

16 Department of Clinical Sciences and Community Health, Università degli Studi

17 Fondazione Ca' Granda Ospedale Maggiore Policlinico

18 Via Commenda, 12 - 20122 Milan, Italy

19 Tel: +39.02.5503.2318; fax: +39.02.50320264; e-mail: paolo.vercellini@unimi.it

20

21

22

23 ABSTRACT

24 Endometriosis infiltrating the bowel can be treated medically in accurately selected women not
25 seeking conception and without overt obstructive symptomatology. When the rectosigmoid junction
26 is involved, the probabilities of intestinal symptoms relief, undergoing surgery after treatment
27 failure, and developing bowel obstruction during hormonal treatment are around 70%, 10%, and 1-
28 2%, respectively. When the lesion infiltrates exclusively the mid-rectum, thus in cases of true
29 rectovaginal endometriosis, the probabilities of intestinal symptoms relief and undergoing surgery
30 are about 80% and 3%, respectively. Endometriotic obstructions of the rectal ampulla have not been
31 reported. A recto-sigmoidoscopy or colonoscopy should be performed systematically before starting
32 medical therapies, also to rule out malignant tumours arising from the intestinal mucosa.
33 Progestogens are safe, generally effective, well tolerated, inexpensive, and should be considered as
34 first-line medications for bowel endometriosis. Independently of symptom relief, intestinal lesions
35 should be checked periodically to exclude nodule progression during hormonal treatment.

36

37

38 KEYWORDS

39 Endometriosis, bowel, pelvic pain, medical treatment, progestogens, GnRH agonists.

40

41

42 INTRODUCTION

43 The bowel is the extragenital site most frequently affected by endometriosis [1,2]. It is estimated
44 that 1 in 10 women with endometriosis harbours deep bowel lesions infiltrating not only the serosa
45 and the sub-serosal tissue but also the muscular layer of the bowel wall. [2–4].

46 Bowel endometriosis may cause functional, irritative-type symptoms (e.g., diarrhoea,
47 intestinal cramping, hematochezia, passage of mucus) originating from the cyclic release of
48 mediators of inflammation, and mechanical, obstructive-type symptoms (e.g., constipation and
49 abdominal bloating), originating from enlarging nodules, intestinal angulation and strictures, and
50 fibrotic tissue retraction. Moreover, some symptoms are associated with specific lesions (e.g., cyclic
51 dyschezia and tenesmus are typical of rectal endometriosis) [5,6].

52 In patients with severe sub-occlusive symptoms, there is no alternative to surgery. However,
53 in many women, bowel endometriosis does not cause overt obstruction to faecal transit. Thus, when
54 conception is not an issue, medical treatment might constitute a therapeutic alternative, especially
55 considering that resection of endometriotic lesions with opening of the intestinal lumen may be
56 followed by complications such as suture leakage, rectovaginal fistula formation, anastomosis
57 stenosis, atonic bladder, and de novo bowel dysfunction [7–10]. The magnitude of the risk is
58 associated also with the distance between the endometriotic lesion and the anal verge and with the
59 coexistence of multiple lesions requiring more than one excision or segmental resection of a long
60 intestinal tract [11–14]. Thus, identifying the exact location and anatomic characteristics of
61 endometriotic bowel lesions appears important to correctly inform women's decisions [3,15,16].

62 The objectives of this narrative review are to define the pathological and endocrine basis
63 underpinning the hormonal therapy of bowel endometriosis, synthesize the published evidence on
64 the effect of available drugs in women with rectosigmoid and rectovaginal endometriosis
65 separately, and propose a three-tiered risk stratification system to be used in patients not seeking
66 conception and without frankly obstructive lesions.

67 Ileocecal endometriosis and the rare, isolated nodules of the small bowel are not considered
68 here because the high risk of intestinal obstruction associated with these types of lesions almost
69 always mandates surgical resection [17,18].

70 We aimed at retrieving reports of studies including patients with a definite diagnosis of
71 endometriosis infiltrating the muscular layer of the mid-rectum (rectovaginal endometriosis), and of
72 the proximal rectum and rectosigmoid junction (colorectal or rectosigmoid endometriosis). Only
73 articles written in English and published in peer-reviewed journals in the last two decades were
74 included. Case reports were considered separately with the specific intent of identifying additional
75 patients who experienced occlusive events during medical treatment and that were not included in
76 the considered studies.

77

78 ANATOMICAL AND HISTOLOGICAL PREMISES

79 Probably due to local anatomical and physiological factors, endometriotic lesions of the left
80 colon are much more frequent than those infiltrating the right colon [2]. Left lesions comprise those
81 involving the rectosigmoid junction (proximal rectum plus distal sigmoid) and those above the
82 rectosigmoid junction (nodules of the mid- and proximal sigmoid) [19,20]. Right infiltrating lesions
83 generally involve the terminal ileum and the cecum. Endometriosis of the appendix is not
84 considered in this review. Lesions infiltrating the mid-rectum, that is, below the rectosigmoid
85 junction, are usually part of complex nodule or plaques of the deepest portion of the Douglas pouch,
86 often infiltrating also the posterior vaginal fornix in addition to the anterior rectal wall [21].
87 Multiple lesions may coexist at different sites. With the exception of the terminal ileal loop, isolated
88 small bowel nodules are very rare.

89 Endometriotic bowel lesions present three distinct histologic components, i) the usual
90 ectopic endometrial-like mucosa; ii) smooth muscle fibres; iii) fibrous connective tissue [1]. The
91 observation of a muscular component is not surprising whenever endometriosis infiltrates the wall
92 of hollow viscera (e.g., bowel, bladder, ureter, vagina). The fibrotic component originates from

93 tissue injury and remodelling induced by local inflammation associated with ectopic endometrium
94 metabolic activity and, possibly, repeated micro-haemorrhages [22].

95 According to the retrograde menstruation theory, for endometriotic lesions to develop,
96 particular anatomic conditions favouring endometrial cells shelter and implantation are needed. In
97 the case of bowel endometriosis, this anatomical niche can be constituted by a physiologic intestinal
98 flexure in close proximity with the salpinges, such as the rectosigmoid and ileocolic junctions
99 [2,17], or by the juxtaposition of the anterior rectal wall and the posterior vaginal wall [21]. The
100 final result of this pathological healing process is the formation of a sort of desmoplastic nodule.
101 Intestinal plication around an endometriotic nodule is possible when an abundant mesocolon is
102 present, and angulation and stricture may result as a consequence of scar retraction. In rectovaginal
103 lesions, the coalescence of the anterior rectal and posterior vaginal walls leads to the formation of a
104 fibrotic plaque that abolishes the distal portion of the Douglas pouch, usually without causing strict
105 bowel angulation [21].

106

107 RATIONALE FOR HORMONAL TREATMENT OF BOWEL ENDOMETRIOSIS

108 Progesterone receptors are expressed not only in the ectopic mucosa but also in the smooth muscle
109 fibres of endometriotic nodules infiltrating the colon [23]. Accordingly, an effect should be
110 expected on two out three components of these deep lesions. In addition, the anti-inflammatory
111 properties of progestogens [24,25] might influence long-term fibrosis remodelling. However, a
112 major impact of medical therapies on the often-predominant fibrotic component seems unlikely.
113 Overall, nodules might undergo volume reduction over time, but fibrotic scarring, and thus
114 angulation and stricture, may not subside.

115 More in general, two distinct therapeutic mechanisms can be hypothesized for the hormonal
116 treatment of bowel endometriosis, one local, based on oestrogen and progesterone receptor
117 expression of individual lesions, and one systemic, based on inhibition of the hypothalamic-
118 pituitary-ovarian axis. Defining the respective importance of the two mechanisms would be

119 relevant. In fact, it is currently assumed that a large part of endometriotic lesions might be
120 refractory to the use of progestogens due to local progesterone resistance [26]. If this is true,
121 theoretically progestogens should not be used to treat deep bowel endometriosis. However, if the
122 systemic effect is more important, progestogens could be used not aiming at a direct local effect,
123 but rather with the intent of preventing ovulation and menstruation, thus reducing the metabolic and
124 proliferative activity of the ectopic mucosa through the induction of a stable hypo-oestrogenic
125 milieu. This *per se* would abate the intra- and perilesional inflammation. In this case, suppression of
126 the gonadal activity should attain partial lesion regression or temporary avoidance of progression
127 independently of receptor status [27].

128 Ferrero *et al.* [28] evaluated variation in rectovaginal endometriotic nodule volume in
129 women treated with progestogens as monotherapy ($n=44$) or combined with letrozole ($n=8$),
130 oestrogen-progestogen contraceptive pills ($n=30$), or triptorelin plus tibolone ($n=10$). At
131 ultrasonography assessment, nodule volume decreased by about 20% after 6 months of therapy, and
132 about 30% after 12 months, without significant differences between study drugs. Nodule volume
133 decreased in 74% of the participants but increased by around 20% in 12% of them.

134 Egekvist *et al.* [29] followed 80 women with rectosigmoid or rectovaginal nodules treated
135 for at least 12 months with a levonorgestrel-releasing intrauterine device (LNG-IUD; $n=49$), an oral
136 contraceptive ($n=12$), a progestogen ($n=9$), or a combination of therapies ($n=10$). The nodule length
137 and width increased in nine and six patients, respectively. During the study period, surgery was
138 required in 6% of the patients. Of note, the LNG-IUD does not inhibit ovulation except for a few
139 months after insertion [30], and acute rectosigmoid obstruction during LNG-IUD use has been
140 described [31].

141 Netter *et al.* [32] assessed rectosigmoid nodule measures variation in 43 women who
142 underwent two MRIs at least 12 months apart. Nodule progression or regression was defined as,
143 respectively, $\geq 20\%$ increase or $\geq 20\%$ decrease in length or in thickness. Any nodule with $< 20\%$
144 variation was defined as stable. Stability, progression or regression was observed in 60%, 28%, and

145 12% of the women, respectively. Moreover, progression was detected in more than one-third of
146 women who never experienced amenorrhoea, but in no patient who experienced continuous
147 amenorrhoea during therapy with GnRH agonists, progestogens, or combined oral contraceptives.
148 The risk of progression was inversely related to the length of periods of amenorrhoea.

149 Barra *et al.* [33] treated 83 women with symptomatic rectosigmoid nodules with oral
150 dienogest, 2 mg/day. Mean nodule volume, as assessed at transvaginal ultrasonography, decreased
151 by 7.5% after 6 months of progestogen therapy, and by 22.5% after 12 months. Endometriotic
152 nodules regressed in 53% of the participants, remained stable in 35%, and progressed (an increase
153 of $\geq 10\%$) in 12%.

154 Nodule volume variation is not necessarily associated with symptom variation. As an
155 example, Netter *et al.* [32] reported persistence of pain symptoms in the vast majority of women in
156 whom the nodule regressed or remained stable. On the other hand, Egekvist *et al.* [29] observed that
157 progression of nodule volume dimensions occurred without worsening of symptoms or health-
158 related quality of life. Barra *et al.* [33] also confirmed that the increase in endometriotic nodule
159 volume during dienogest therapy was not always associated with worsening of clinical symptoms.

160

161 ENDOMETRIOSIS OF THE MID-RECTUM (RECTOVAGINAL ENDOMETRIOSIS)

162 A total of 1232 patients were included in 23 studies published in the period January 2000-May 2020
163 (prospective cohort, $n=11$; patient preference trial, $n=6$; retrospective cohort, $n=3$; randomised
164 controlled trial (RCT), $n=2$; before and after study, $n=1$; Table 1). The experimental study drug was
165 a progestin in 11 studies, an oestrogen-progestogen combination (OPC) in 3, an aromatase inhibitor
166 in 3, a GnRH agonist in 2, vaginal danazol in 2, an LNG-IUD in 1, and an etonogestrel-releasing
167 implant in 1. The route of administration was mostly oral for progestogens and OPC, but also the
168 vaginal, intramuscular, transdermal and intra-uterine route were assessed (Table 1).

169 The symptoms referred by recruited women were not always precisely described and
170 accurately measured. Overall, the probability of partial or complete relief was 100% for rectal

171 tenesmus, feeling of incomplete evacuation and cyclic rectal bleeding, 92% for dyschezia, 64% for
172 constipation, 58% for diarrhoea, 38% for passage of mucus, and 37% for abdominal bloating. In
173 addition, dysmenorrhoea subsided in 78% of the considered women, deep dyspareunia in 77%, and
174 non-cyclic pelvic pain in 73%.

175 A total of 38 women (3%) underwent surgery during the study period (persistence or
176 worsening of pain symptoms, $n=15$; lesion size progression, $n=3$; indication not reported, $n=20$). No
177 patient experienced bowel obstruction while using hormonal medications.

178

179 ENDOMETRIOSIS OF THE PROXIMAL RECTUM AND DISTAL SIGMOID

180 (RECTOSIGMOID JUNCTION ENDOMETRIOSIS)

181 In the considered period, a total of 588 patients were included in 10 studies (prospective cohort,
182 $n=5$; retrospective cohort, $n=5$; Table 2). However, 238 participants were enrolled in a single study
183 [34]. The experimental study drug was a progestin in 3 studies, an OPC in 1, an aromatase inhibitor
184 in 1, a GnRH agonist in 1, and multiple hormonal drugs in 4. The route of administration was
185 always oral except for one study investigating the effect of a GnRH agonist injected intramuscularly
186 in a depot formulation (Table 2).

187 Again, the description and assessment of symptoms sometimes were suboptimal. Overall,
188 the probability of partial or complete relief was 100% for diarrhoea and passage of mucous, 98%
189 for constipation, 90% for a feeling of incomplete evacuation and cyclic hematochezia, 82% for
190 intestinal cramping, and 79% for abdominal bloating. In addition, dysmenorrhoea subsided in 80%
191 of the considered women, deep dyspareunia in 78%, and non-cyclic pelvic pain in 67%.

192 A total of 123 women (21%) underwent surgery during the study period (persistence or
193 worsening of pain symptoms, $n=79$; lesion size progression, $n=26$; intolerance of medical treatment,
194 $n=11$; indication not reported, $n=6$; occlusive symptoms, $n=1$). Of note, 95 out of these 123 women
195 were described in a single study [34]. Excluding this outlier, the probability of undergoing surgery

196 despite medical therapy was 8% (28/350; persistence or worsening of pain symptoms, $n=11$;
197 intolerance of medical treatment, $n=11$; indication not reported, $n=6$).

198

199 BOWEL OBSTRUCTION DURING MEDICAL TREATMENT

200 Complete intestinal obstruction caused by endometriotic stricture is rare, as it is estimated to occur
201 in $< 1\%$ of patients with bowel lesions [31,35]. However, for women considering medical treatment
202 as an alternative to surgery, it would be important to know not only the general risk of such
203 complication but the specific risk of this event while using suppressive therapies. In fact, the
204 volume of 5%-10% of endometriotic intestinal nodules increases during pharmacological treatment.
205 Only one case of sub-acute bowel obstruction in a woman with rectosigmoid junction endometriosis
206 was described in the 33 studies considered in this review [34]. The type of medication used was not
207 reported.

208 Among the case reports searched through PubMed, 15 additional cases of bowel obstruction
209 during medical treatment use (isolated sigmoid colon endometriosis, $n=3$; rectosigmoid junction
210 endometriosis, $n=12$) were identified. Ferrero *et al.* [36], Constantin *et al.* [37] and Millochau *et al*
211 [38] observed sub-acute [36,38] or acute [37] intestinal obstruction caused by an endometriotic
212 nodule infiltrating the sigmoid colon, in all cases after four years of cyclic [36,37] or continuous
213 [38] treatment with a combined oral contraceptive.

214 Navajas-Laboa *et al.* [39] reported a case of endometriotic rectosigmoid junction obstruction
215 occurred one month after discontinuation of an oral contraceptive used for more than 20 years.
216 Scioscia *et al.* [40] briefly described seven women who underwent laparoscopic colorectal resection
217 owing to progression of rectosigmoid stenosis after 9-16 months of daily oral therapy with
218 desogestrel 75 μg ($n=3$), dienogest 2 mg ($n=2$), or nor-ethisterone acetate 2.5 mg ($n=2$). All nodules
219 were larger than 4 cm. Whelton and Bhowmick reported a case of acute bowel obstruction due to
220 stenosis of the rectosigmoid junction in a woman wearing an LNG-IUD as a treatment for severe
221 deep endometriosis [31].

222 De Jong *et al.* described five patients who underwent emergency surgery because of an
223 endometriotic stricture of the rectosigmoid junction. Three of these women used medical treatment,
224 but it is unclear whether the bowel obstruction ensued during the use of respectively, a GnRH
225 agonist, an LNG-IUD, and a progestogen, or if these drugs were used in the past for a limited time
226 period. In fact, the authors only stated: “three patients were already treated with GnRH agonists or
227 other hormone therapies” [35].

228 Of relevance, intestinal obstructions ensued during therapy for sigmoid or rectosigmoid
229 lesions, but not for exclusively mid-rectal nodules. This supports the notion that the development of
230 strict angulation of a bowel tract is a pre-requisite for occlusion to occur. An increase in
231 endometriotic nodule dimension may further facilitate the process, as protrusion within a strictly
232 angulated intestinal lumen may easily result in worsening of the stenosis to the point of impeding
233 faecal transit. Importantly, for most of the reported cases, the baseline anatomic characteristics of
234 bowel lesions were not described. Therefore, it is not possible to exclude that some of the women
235 who experienced intestinal occlusion were not candidates to medical treatment according to
236 currently agreed selection criteria.

237

238 MEDICAL THERAPY FOR BOWEL ENDOMETRIOSIS: WHEN AND HOW.

239 The quality of the available evidence on medical therapy for bowel endometriosis is suboptimal.
240 Most studies were non-comparative. Several drugs were evaluated, often grouped in the same
241 series, thus impeding definition of the effect of individual compounds and ascertainment of
242 differences between therapies. Sometimes two different molecules were combined. Treatment
243 periods were highly variable, ranging from a few months to years. It was not always possible to
244 extract the precise location of bowel lesions, especially when the generic definition “colorectal
245 endometriosis” was used. Thus, it may not be excluded that women at different prognosis were
246 studied together, especially when patients with multiple lesions were included. Indeed, rectovaginal
247 and recto-sigmoid junction lesions may coexist. Finally, when pain relief is considered,

248 discriminating the specific response to treatment of bowel endometriosis from that of other pelvic
249 lesions seems difficult.

250 As a consequence, only general conclusions can be drawn from the assessment of published
251 data. When the lesion is located above the mid-rectum, medical treatment should not be suggested if
252 the degree of lumen stenosis is $\geq 60\%$, or if the lesion infiltrates $\geq 50\%$ of the bowel circumference,
253 or if the largest nodule diameter is >3 cm. In fact, the likelihood of substantial symptom
254 improvement and definitive avoidance of surgery seems strictly related to the above lesion
255 characteristics [3,4,41].

256 Moreover, medical therapy should never be suggested as an alternative to surgery for bowel
257 endometriosis in patients with i) severe sub-occlusive intestinal symptoms, ii) ureteral stenosis with
258 hydroureteronephrosis, iii) adnexal masses > 5 cm or with suspect ultrasonographic appearance, and
259 iv) current pregnancy desire. Women wishing to conceive in the future should also be carefully
260 counselled, not only because all the available hormonal medications interfere with ovulation, but
261 also because bowel obstruction and perforation during pregnancy and ovarian stimulation have been
262 reported [42–44]. In addition, intestinal procedures are more complex in the presence of a gravid
263 uterus and are associated with risk of harms to both the mother and the foetus [45].

264 In the absence of the above conditions, women should be informed in detail on the
265 advantages and disadvantages of medical and surgical options. Patients should know that hormonal
266 drugs might control, but not cure bowel endometriosis. Therefore, if medical treatment is chosen,
267 this means using medications for years, possibly until the physiologic menopause. On the other
268 hand, women should also know that excisional surgery as an isolated measure might not guarantee
269 complete and/or long-lasting symptom relief. To reduce the risk of symptom and lesion recurrence,
270 which is about 50% in 5 years [3,41,46,47], postoperative hormonal therapy may be needed anyway
271 for an indefinite period of time.

272 Women desiring to avoid surgery, willing to use medications for years, who are
273 psychologically tolerant of amenorrhoea and ready to deal with possible side effects of medications,

274 and without contraindications to available hormonal drugs, should then be informed about the
275 absolute probability of i) experiencing pain and bowel symptoms relief, ii) undergoing surgery
276 anyway for multiple reasons, iii) suffering episodes of frank bowel obstruction during medical
277 treatment. This stage of the information process should be based on the precise location and
278 characteristics of the lesion. In particular, patients should be aware that when the rectosigmoid
279 junction is involved, the probability of intestinal symptoms relief is around 70%, and of undergoing
280 surgery anyway around 10%. The risk of bowel obstruction is presumably between 1% and 2%. In
281 most but not all cases, surgery can still be planned without the need for emergency procedures.

282 On the other hand, lesion dimension has little impact on the probability of success of
283 medical therapy when the lesion infiltrates exclusively the mid-rectum as, to our knowledge,
284 endometriotic obstructions of the rectal ampulla have not been reported. In case of true rectovaginal
285 endometriosis, the probability of intestinal symptoms relief is around 80%, and that of undergoing
286 surgery anyway for symptom persistence about 3%.

287 When multiple lesions are present, the shared decision process should focus on the lesion at
288 worst prognosis. A recto-sigmoidoscopy or colonoscopy, in addition to transvaginal
289 ultrasonography and MRI or other imaging techniques [15,16], should be suggested systematically
290 before starting medical therapies, not only to verify the degree of lumen stenosis but also to rule out
291 malignant tumours arising from the intestinal mucosa.

292 Women should also be aware that deciding between medical and surgical treatment is not
293 necessarily an “either/or” decision but may be viewed as a stepwise approach. In a stepped care
294 model, hormonal treatments should be tried first, resorting to surgery in women who do not respond
295 to or do not tolerate medications [48]. However, when all the above selection criteria have been
296 satisfied, generally no more than half of the patients with symptomatic bowel endometriosis
297 actually remain available for a trial of medical therapy [20]. Obviously, the accurate selection of
298 candidates for medical treatment on one hand reduces the number of potential users but, on the
299 other hand, increases the likelihood of success and overall patient satisfaction with this choice.

300 Most of the evidence on medical treatment for bowel endometriosis concerns the use of
301 progestogens or OPC. These compounds are safe, generally effective, well-tolerated, inexpensive,
302 and may be used for years. For these reasons, progestogens and continuous, low-dose OPC should
303 be considered as first-line medications also for bowel endometriosis. A difference in the magnitude
304 of the effect of these two drugs has not been demonstrated. Moreover, intestinal sub-acute
305 obstruction has been reported during treatment with both, progestogens [31,35,40] and OPC [36–
306 39].

307 However, the pathogenic premise behind medical treatment for deep endometriosis is
308 different from that for ovarian endometriomas. In the latter case, the objective is inhibiting
309 ovulation independently of the oestrogen content of the medication used, whereas when dealing
310 with infiltrating lesions the objective is achieving the maximum possible disease quiescence to
311 avoid lesion progression [30,48].

312 Casper questioned the role of OPC in the management of endometriosis based on the
313 hypothesis that owing to the supra-physiologic oestrogen content, these combinations may not
314 adequately suppress lesions and relieve symptoms [24]. In addition, the results of a small RCT
315 suggested a potentially detrimental role of even small amounts of a natural oestrogen [49]. The
316 stimulating action of oestrogens on ectopic endometrium are generally effectively counteracted by
317 progestogens when using OPC. Nevertheless, until this issue will be definitively disentangled,
318 prescribing progestogen monotherapies to minimize the risk of lesion progression seems wiser
319 when treating women with bowel endometriosis. Oral dienogest, 2 mg/day and nor-ethisterone
320 acetate, 2.5 mg/day are similarly effective, although the former, costlier, compound seems better
321 tolerated [50].

322 Progestogens are usually associated with several side effects in a large proportion of users.
323 However, in most cases, untoward effects are not severe enough to cause drug discontinuation. An
324 exception is irregular bleeding, as it may cause pelvic pain and bowel symptoms worsening, is
325 scarcely tolerated, and may limit treatment adherence [30,48]. Women must be informed in

326 advanced that around one-third of women experiences repeated irregular bleeding and associated
327 pelvic pain during progestogen treatment. Anticipating and describing these events may reduce
328 anxiety, and providing information on tailored cycling may reduce the risk of drop out.
329 Discontinuing progestogen assumption for one week generally allows successful management of
330 breakthrough bleeding or prolonged spotting [30]. The frequency of these events generally
331 decreases over time. Starting treatment with a GnRH agonist for a few months and then switching
332 to an oral progestogen, may reduce the incidence of unexpected and painful bleeding episodes [51].

333 Bowel lesions, especially when infiltrating the sigmoid colon and the rectosigmoid junction,
334 should be checked periodically with imaging techniques [15,16], with the aim of identifying nodule
335 progression during progestogen treatment despite partial or complete symptom relief [33].
336 Moreover, kidneys and ureters should also be checked regularly to rule out silent progressive
337 hydroureteronephrosis, especially in women with large rectovaginal plaques extending laterally
338 toward the pelvic sidewall [14].

339

340 A LESION-BASED, THREE-TIERED RISK STRATIFICATION SYSTEM FOR BOWEL 341 ENDOMETRIOSIS

342 The definition “bowel endometriosis” comprises different anatomical conditions associated with
343 different clinical patterns. In particular, the likelihood of safely alleviating intestinal symptoms and
344 avoiding surgery varies according to lesion location.

345 Bowel obstruction is probable when the lumen is intrinsically narrow, such as in cases of
346 involvement of the last ileal loop and ileocecal valve [17,18]. Obstruction is possible when lesions
347 infiltrate the wall of the sigmoid and the rectosigmoid junction, as the abundant mesocolon easily
348 allows intestinal angulation around the nodule, which thus may act as a wedge impinging on a loop
349 strictly fixed by fibrotic tissue. Conversely, the mid-rectum, which corresponds to the Douglas
350 pouch, only has an anterior peritoneal covering. This, together with the large calibre and

351 distensibility of the rectal ampulla, renders sharp angulation and stenotic obstruction mechanically
352 unlikely [14,20,48].

353 To define the therapeutic trade-offs that should inform patient choices, the potential harms
354 of surgery for different bowel lesions should also be considered. Although lesion shaving is being
355 fostered [8], actually nodulectomy (disk excision) and segmental resection are the procedures more
356 frequently performed in case of bowel stenosis due to infiltrating endometriosis [3,4,10,13].
357 Proximal sigmoid nodule excision or segmental resection require standard surgically capabilities
358 and are associated with a low risk of complications [9,12]. A temporary derivative ostomy is
359 generally not necessary. Colorectal resection for rectosigmoid junction endometriosis may be
360 technically demanding and is associated with a 5% risk of severe short- and medium-term
361 complications [10,12]. The decision to confection an ostomy depends on local protocols, and
362 variable percentages have been reported [4,12,13]. Patients requiring low-anterior rectal resection
363 for rectovaginal endometriosis infiltrating the mid-rectum should be referred to centres of expertise
364 where abdominal surgeons and gynaecologists specifically trained to manage complex pelvic
365 endometriosis are available. The posterior vaginal fornix must be frequently excised at the same
366 time, thus increasing the likelihood of rectovaginal fistula formation. For this reason, a protective
367 ostomy is frequently performed. The risk of severe complication is around 10% [4,10,12,14,20].

368 Based on these considerations, a three-tiered risk stratification system could be envisaged
369 when managing bowel endometriosis. As endometriosis of the proximal sigmoid is associated with
370 a moderate risk of obstruction, an indefinite likelihood of improvement during medical treatment,
371 and a low risk of surgical complications, excision should be preferred.

372 Endometriosis of the rectosigmoid junction is also associated with a moderate risk of
373 obstruction, but sufficient evidence exists to anticipate a fairly good effect of medical therapy. The
374 risk of surgical complications is also moderate. In this sort of therapeutic equipoise, the value of the
375 two treatment options appears similar. Pharmacological therapy could be tried first, resorting to
376 surgery in case of inefficacy of or intolerance to medications.

377 Rectovaginal endometriosis is not at risk of obstruction and usually responds well to
378 hormonal compounds. Radical excision of this type of lesions carries a moderate-high risk of
379 surgical complications [10,14]. Thus, medical treatment should be preferred.

380 Several other factors may influence the final decision, including the presence of multiple
381 lesions, previous complex surgical procedures and overall surgical risk, age, and the long-term total
382 expected costs of the different therapeutic options. In addition, the role of patients is here
383 particularly important, as different women may be willing to accept different levels of surgical risks
384 or may tolerate differently the same drug side effects. Whether to accept potential surgical
385 morbidity or use medications for years is a very personal choice that should be based on complete,
386 detailed, and unbiased information.

387 SUMMARY

388 The quality of the evidence on medical therapy for bowel endometriosis is suboptimal and only
389 general conclusions can be drawn. Medical treatment should not be suggested to women wishing to
390 conceive, and also when severe sub-occlusive symptoms are present, the degree of lumen stenosis is
391 $\geq 60\%$, or the lesion infiltrates $\geq 50\%$ of the bowel circumference, or the largest nodule diameter is
392 >3 cm. Patients should be informed in detail about the advantages and disadvantages of medical and
393 surgical options. Hormonal drugs might control, but not cure bowel endometriosis. This means
394 using medications for long periods of time. However, excisional surgery as an isolated measure
395 may not guarantee complete and/or long-lasting symptom relief, and postoperative hormonal
396 therapy may be needed anyway. The information process should be based on the location and
397 characteristics of the lesion. Approximately two-thirds of accurately selected patients with
398 rectosigmoid endometriosis and three-fourths of those with rectovaginal lesions can be managed
399 successfully with hormonal drugs. Progestogens are safe, effective, generally well-tolerated,
400 inexpensive, may be used for years, and should be considered as first-line medications. Around one-
401 third of women experiences repeated irregular bleeding with associated pelvic pain during
402 continuous progestogen treatment, and instructions should be provided on how to manage these
403 events. The risk of obstruction during therapy is low in women with rectosigmoid junction
404 endometriosis, and virtually absent in those with rectovaginal disease. However, bowel lesions
405 should be checked periodically with imaging techniques to identify possible nodule progression
406 during medical treatment despite symptom relief.

407

408 CONFLICT OF INTEREST STATEMENT

409 None.

410

411 PRACTICE POINTS

412

413 • Medical treatment is a valuable therapeutic option that could be proposed in selected women
414 with bowel endometriosis.

415

416 • About two-thirds of the patients with rectosigmoid endometriosis and three-fourths of those
417 with rectovaginal lesions can be managed successfully with hormonal drugs, provided strict
418 selection criteria are fulfilled.

419

420 • Endometriotic bowel lesions should be checked periodically with imaging techniques to
421 identify possible nodule progression during medical treatment despite symptom relief.

422

423 RESEARCH AGENDA

424

425 • Comparative effectiveness research on medical treatment versus surgery for endometriosis
426 of the proximal rectum and rectosigmoid junction (colorectal endometriosis)

427

428 • Comparative effectiveness research on medical treatment versus surgery for endometriosis
429 of the mid-rectum (rectovaginal endometriosis)

430

431 • GnRH agonists followed by progestogens to reduce breakthrough bleeding.

432

433 REFERENCES

- 434 [1] Chapron C, Chopin N, Borghese B, Foulot H, Dousset B, Vacher-lavenu MC, et al. Deeply
435 infiltrating endometriosis : pathogenetic implications of the anatomical distribution
436 2006;21:1839–45. <https://doi.org/10.1093/humrep/del079>.
- 437 [2] Vercellini P, Chapron C, Fedele L, Gattei U, Daguati R, Crosignani PG. Evidence for
438 asymmetric distribution of lower intestinal tract endometriosis. *BJOG An Int J Obstet*
439 *Gynaecol* 2004;111:1213–7. <https://doi.org/10.1111/j.1471-0528.2004.00453.x>.
- 440 [3] Abrão MS, Petraglia F, Falcone T, Keckstein J, Osuga Y, Chapron C. Deep endometriosis
441 infiltrating the recto-sigmoid : critical factors to consider before management. *Hum Reprod*
442 *Update* 2015;21:329–39. <https://doi.org/10.1093/humupd/dmv003>.
- 443 [4] Nezhat C, Li A, Falik R, Copeland D, Razavi G, Shakib A, et al. Bowel endometriosis:
444 diagnosis and management. *Am J Obstet Gynecol* 2018;218:549–62.
445 <https://doi.org/10.1016/j.ajog.2017.09.023>.
- 446 [5] Vercellini P. Endometriosis: What a pain it is. *Semin Reprod Endocrinol* 1997;15:251–61.
447 <https://doi.org/10.1055/s-2008-1068755>.
- 448 [6] Roman H, Ness J, Suciú N, Gourcerol G, Leroi AM, Tuech JJ, et al. Are digestive symptoms
449 in women presenting with pelvic endometriosis specific to lesion localizations ? A
450 preliminary prospective study †. *Hum Reprod* 2012;27:3440–9.
451 <https://doi.org/10.1093/humrep/des322>.
- 452 [7] Roman H, Vassilieff M, Tuech JJ, Huet E, Savoye G, Marpeau L, et al. Postoperative
453 digestive function after radical versus conservative surgical philosophy for deep
454 endometriosis infiltrating the rectum. *Fertil Steril* 2013;99.
455 <https://doi.org/10.1016/j.fertnstert.2013.01.131>.
- 456 [8] Roman H, Bridoux V, Tuech JJ, Marpeau L, Da Costa C, Savoye G, et al. Bowel dysfunction
457 before and after surgery for endometriosis. *Am J Obstet Gynecol* 2013;209:524–30.
458 <https://doi.org/10.1016/j.ajog.2013.04.015>.

- 459 [9] Balla A, Quaresima S, Subiela JD, Shalaby M, Petrella G, Sileri P. Outcomes after
460 rectosigmoid resection for endometriosis: a systematic literature review. *Int J Colorectal Dis*
461 2018;33:835–47. <https://doi.org/10.1007/s00384-018-3082-y>.
- 462 [10] Ferrero S, Stabilini C, Barra F, Clarizia R, Roviglione G, Ceccaroni M. Bowel resection for
463 intestinal endometriosis. *Best Pract Res Clin Obstet Gynaecol* 2020.
464 <https://doi.org/10.1016/j.bpobgyn.2020.05.008>.
- 465 [11] Trencheva K, Morrissey KP, Wells M, Mancuso CA, Lee SW, Sonoda T, et al. Identifying
466 important predictors for anastomotic leak after colon and rectal resection: Prospective study
467 on 616 patients. *Ann Surg* 2013;257:108–13.
468 <https://doi.org/10.1097/SLA.0b013e318262a6cd>.
- 469 [12] Ret Dávalos ML, De Cicco C, D’Hoore A, De Decker B, Koninckx PR. Outcome after
470 rectum or sigmoid resection: A review for gynecologists. *J Minim Invasive Gynecol*
471 2007;14:33–8. <https://doi.org/10.1016/j.jmig.2006.07.015>.
- 472 [13] Abrão MS, Borrelli GM, Clarizia R, Kho RM, Ceccaroni M. Strategies for Management of
473 Colorectal Endometriosis. *Semin Reprod Med* 2017;35:065–71. [https://doi.org/10.1055/s-](https://doi.org/10.1055/s-0036-1597307)
474 [0036-1597307](https://doi.org/10.1055/s-0036-1597307).
- 475 [14] Vercellini P, Carmignani L, Rubino T, Barbara G, Abbiati A, Fedele L. Surgery for deep
476 endometriosis: A pathogenesis-oriented approach. *Gynecol Obstet Invest* 2009;68:88–103.
477 <https://doi.org/10.1159/000219946>.
- 478 [15] Biscaldi E, Barra F, Roberti Maggiore UL, Ferrero S. Other imaging techniques: double-
479 contrast barium enema, endoscopic ultrasonography, multidetector CT enema, and computed
480 tomography colonoscopy. *Best Pract Res Clin Obstet Gynaecol* 2020.
481 <https://doi.org/10.1016/j.bpobgyn.2020.05.011>.
- 482 [16] Ferrero S, Barra F, Scala C, Condous G. Ultrasonography for bowel endometriosis. *Best*
483 *Pract Res Clin Obstet Gynaecol* 2020. <https://doi.org/10.1016/j.bpobgyn.2020.05.010>.
- 484 [17] Fedele L, Berlanda N, Corsi C, Gazzano G, Morini M, Vercellini P. Ileocecal endometriosis:

- 485 Clinical and pathogenetic implications of an underdiagnosed condition. *Fertil Steril*
486 2014;101:750–3. <https://doi.org/10.1016/j.fertnstert.2013.11.126>.
- 487 [18] Sali PA, Yadav KS, Desai GS, Bhole BP, George A, Parikh SS, et al. Small bowel
488 obstruction due to an endometriotic ileal stricture with associated appendiceal endometriosis:
489 A case report and systematic review of the literature. *Int J Surg Case Rep* 2016;23:163–8.
490 <https://doi.org/10.1016/j.ijscr.2016.04.025>.
- 491 [19] Vercellini P, Buggio L, Borghi A, Monti E, Gattei U, Frattaruolo MP. Medical treatment in
492 the management of deep endometriosis infiltrating the proximal rectum and sigmoid colon: a
493 comprehensive literature review. *Acta Obstet Gynecol Scand* 2018;97:942–55.
494 <https://doi.org/10.1111/aogs.13328>.
- 495 [20] Vercellini P, Frattaruolo MP, Rosati R, Dridi D, Roberto A, Mosconi P, et al. Medical
496 treatment or surgery for colorectal endometriosis ? Results of a shared decision-making
497 approach. *Hum Reprod* 2018;33:202–11. <https://doi.org/10.1093/humrep/dex364>.
- 498 [21] Vercellini P, Aimi G, Panazza S, Vicentini S, Pisacreta A, Crosignani PG. Deep
499 endometriosis conundrum: Evidence in favor of a peritoneal origin. *Fertil Steril*
500 2000;73:1043–6. [https://doi.org/10.1016/S0015-0282\(00\)00420-9](https://doi.org/10.1016/S0015-0282(00)00420-9).
- 501 [22] Anaf V, Simon P, Fayt I, Noel J. Smooth muscles are frequent components of endometriotic
502 lesions. *Hum Reprod* 2000;15:767–71.
- 503 [23] Noël JC, Chapron C, Bucella D, Buxant F, Peny MO, Fayt I, et al. Estrogen and progesterone
504 receptors in smooth muscle component of deep infiltrating endometriosis. *Fertil Steril*
505 2010;93:1774–7. <https://doi.org/10.1016/j.fertnstert.2008.12.114>.
- 506 [24] Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than
507 combined estrogen-progestin contraceptive pills. *Fertil Steril* 2017;107:533–6.
508 <https://doi.org/10.1016/j.fertnstert.2017.01.003>.
- 509 [25] Vigano P, Candiani M, Monno A, Giacomini E, Vercellini P, Somigliana E. Time to redefi
510 ne endometriosis including its pro-fibrotic nature. *Hum Reprod* 2018;33:347–52.

- 511 <https://doi.org/10.1093/humrep/dex354>.
- 512 [26] Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. *Endocr*
513 *Rev* 2019;40:1048–79. <https://doi.org/10.1210/er.2018-00242>.
- 514 [27] Vercellini P, Vigano P, Buggio L, Barbara G, Somigliana E. Letter to the EDITOR:
515 “Progesterone receptor status predicts response to progestin therapy in endometriosis.” *J Clin*
516 *Endocrinol Metab* 2019;104:2147–8. <https://doi.org/10.1210/jc.2018-02494>.
- 517 [28] Ferrero S, Leone Roberti Maggiore U, Scala C, Di Luca M, Venturini PL, Remorgida V.
518 Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during
519 hormonal therapies. *Arch Gynecol Obstet* 2013;287:447–53. [https://doi.org/10.1007/s00404-](https://doi.org/10.1007/s00404-012-2581-2)
520 [012-2581-2](https://doi.org/10.1007/s00404-012-2581-2).
- 521 [29] Egekvist AG, Graumann O, Marinovskij E, Hansen MS, Forman A, Kesmodel US.
522 Conservative treatment of rectosigmoid endometriosis : A prospective study. *Acta Obstet*
523 *Gynecol Scand* 2019;1139–47. <https://doi.org/10.1111/aogs.13619>.
- 524 [30] Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins
525 and progestins for the management of endometriosis. *Fertil Steril* 2016;106:1552-1571.e2.
526 <https://doi.org/10.1016/j.fertnstert.2016.10.022>.
- 527 [31] Whelton C, Bhowmick A. Acute endometrial bowel obstruction - A rare indication for
528 colonic stenting. *Int J Surg Case Rep* 2013;4:160–3.
529 <https://doi.org/10.1016/j.ijscr.2012.11.007>.
- 530 [32] Netter A, Avout-fourdinier P, Agostini A, Chanavaz-lacheray I, Lampika M, Farella M, et al.
531 Progression of deep infiltrating rectosigmoid endometriotic nodules. *Hum Reprod*
532 2019;34:2144–52. <https://doi.org/10.1093/humrep/dez188>.
- 533 [33] Barra F, Scala C, Leone Roberti Maggiore U, Ferrero S. Long-Term Administration of
534 Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid
535 Endometriosis. *J Clin Med* 2020;9:154. <https://doi.org/10.3390/jcm9010154>.
- 536 [34] Andres MP, Franco R, Mendes P, Hernandez C, Eduardo S, Araújo A, et al. Hormone

- 537 Treatment as First Line Therapy Is Safe and Relieves Pelvic Pain in Women With Bowel
538 Endometriosis. *Einstein (Sao Paulo)* 2019;17.
539 https://doi.org/10.31744/EINSTEIN_JOURNAL/2019AO4583.
- 540 [35] De Jong MJH, Mijatovic V, Van Waesberghe JHTM, Cuesta MA, Hompes PGA. Surgical
541 outcome and long-term follow-up after segmental colorectal resection in women with a
542 complete obstruction of the rectosigmoid due to endometriosis. *Dig Surg* 2009;26:50–5.
543 <https://doi.org/10.1159/000194197>.
- 544 [36] Ferrero S, Camerini G, Venturini PL, Biscaldi E, Remorgida V. Progression of bowel
545 endometriosis during treatment with the oral contraceptive pill. *Gynecol Surg* 2011;8:311–3.
546 <https://doi.org/10.1007/s10397-010-0610-3>.
- 547 [37] Constantin V, Carâp A, Bobic S, Pâun I, Brătîlă E, Socea B, et al. Accurate diagnosis of
548 sigmoid Colon Endometriosis by Immunohistochemistry and transmission electron
549 microscopy - A case report. *Chir* 2015;110:482–5.
- 550 [38] Millochau JC, Abo C, Darwish B, Huet E, Dietrich G, Roman H. Continuous Amenorrhea
551 May Be Insufficient to Stop the Progression of Colorectal Endometriosis. *J Minim Invasive*
552 *Gynecol* 2016;23:839–42. <https://doi.org/10.1016/j.jmig.2016.04.008>.
- 553 [39] Navajas-Laboa M, Orive-Calzada A, Landaluce A, Zabalza-Estevez I, Larena JA, Arévalo-
554 Serna JA, et al. Colonic obstruction caused by endometriosis solved with a colonic stent as a
555 bridge to surgery. *Arab J Gastroenterol* 2015;16:33–5.
556 <https://doi.org/10.1016/j.ajg.2014.10.004>.
- 557 [40] Scioscia M, Scardapane A, Ceccaroni M. Regarding “Continuous Amenorrhea May be
558 Insufficient to Stop the Progression of Colorectal Endometriosis.” *J Minim Invasive Gynecol*
559 2016;23:1203–5. <https://doi.org/10.1016/j.jmig.2016.06.010>.
- 560 [41] Alabiso G, Alio L, Arena S, di Prun AB, Bergamini V, Berlanda N, et al. How to manage
561 bowel endometriosis: The ETIC approach. *J Minim Invasive Gynecol* 2015;22:517–29.
562 <https://doi.org/10.1016/j.jmig.2015.01.021>.

- 563 [42] Setúbal A, Sidiropoulou Z, Torgal M, Casal E, Lourenço C, Koninckx P. Bowel
564 complications of deep endometriosis during pregnancy or in vitro fertilization. *Fertil Steril*
565 2014;101:442–6. <https://doi.org/10.1016/j.fertnstert.2013.11.001>.
- 566 [43] Roman H, Puscasiu L, Lempicki M, Huet E, Chati R, Bridoux V, et al. Colorectal
567 Endometriosis Responsible for Bowel Occlusion or Subocclusion in Women With Pregnancy
568 Intention: Is the Policy of Primary in Vitro Fertilization Always Safe? *J Minim Invasive*
569 *Gynecol* 2015;22:1059–67. <https://doi.org/10.1016/j.jmig.2015.05.023>.
- 570 [44] Anaf V, Nakadi I El, Simon P, Englert Y, Peny M, Fayt I, et al. Sigmoid endometriosis and
571 ovarian stimulation Case reports. *Hum Reprod* 2000;15:790–4.
- 572 [45] Thomin A, Belghiti J, David C, Marty O, Bornes M, Ballester M, et al. Maternal and
573 neonatal outcomes in women with colorectal endometriosis. *BJOG An Int J Obstet Gynaecol*
574 2018;125:711–8. <https://doi.org/10.1111/1471-0528.14221>.
- 575 [46] Vercellini P, Crosignani PG, Abbiati A, Somigliana E, Fedele L, Vigano P. The effect of
576 surgery for symptomatic endometriosis : the other side of the story. *Hum Reprod Update*
577 2009;15:177–88. <https://doi.org/10.1093/humupd/dmn062>.
- 578 [47] Guo S. Recurrence of endometriosis and its control. *Hum Reprod Update* 2009;15:441–61.
579 <https://doi.org/10.1093/humupd/dmp007>.
- 580 [48] Vercellini P, Buggio L, Somigliana E. Role of medical therapy in the management of deep
581 rectovaginal endometriosis. *Fertil Steril* 2017;108:913–30.
582 <https://doi.org/10.1016/j.fertnstert.2017.08.038>.
- 583 [49] Hurst BS, Gardner SC, Tucker KE, Awoniyi CA, Schlaff WD. Delayed Oral Estradiol
584 Combined with Leuprolide Increases Endometriosis-Related Pain. *J Soc Laparoendosc Surg*
585 2000;97–101.
- 586 [50] Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, et al. Norethindrone
587 acetate or dienogest for the treatment of symptomatic endometriosis: A before and after
588 study. *Fertil Steril* 2016;105:734-743.e3. <https://doi.org/10.1016/j.fertnstert.2015.11.016>.

- 589 [51] Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest
590 following gonadotropin-releasing hormone agonist treatment for endometriosis-associated
591 pelvic pain. *Eur J Obstet Gynecol Reprod Biol* 2011;157:212–6.
592 <https://doi.org/10.1016/j.ejogrb.2011.03.012>.
- 593 [52] Fedele L, Bianchi S, Zanconato G, Tozzi L, Raffaelli R. Gonadotropin-releasing hormone
594 agonist treatment for endometriosis of the rectovaginal septum. *Am J Obstet Gynecol*
595 2000;183:1462–7. <https://doi.org/10.1067/mob.2000.108021>.
- 596 [53] Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing
597 intrauterine device in the treatment of rectovaginal endometriosis. *Fertil Steril* 2001;75:485–
598 8. [https://doi.org/10.1016/S0015-0282\(00\)01759-3](https://doi.org/10.1016/S0015-0282(00)01759-3).
- 599 [54] Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of
600 symptomatic rectovaginal endometriosis with an estrogen – progestogen combination versus
601 low-dose norethindrone acetate. *Fertil Steril* 2005;84:1375–87.
602 <https://doi.org/10.1016/j.fertnstert.2005.03.083>.
- 603 [55] Hefler LA, Grimm C, Van Trotsenburg M, Nagele F. Role of the vaginally administered
604 aromatase inhibitor anastrozole in women with rectovaginal endometriosis: A pilot study.
605 *Fertil Steril* 2005;84:1033–6. <https://doi.org/10.1016/j.fertnstert.2005.04.059>.
- 606 [56] Razzi S, Luisi S, Calonaci F, Altomare A, Bocchi C, Petraglia F. Efficacy of vaginal danazol
607 treatment in women with recurrent deeply infiltrating endometriosis. *Fertil Steril* 2007;88:0–
608 5. <https://doi.org/10.1016/j.fertnstert.2006.12.077>.
- 609 [57] Remorgida V, Abbamonte HL, Ragni N, Fulcheri E, Ferrero S. Letrozole and norethisterone
610 acetate in rectovaginal endometriosis. *Fertil Steril* 2007;88:724–6.
611 <https://doi.org/10.1016/j.fertnstert.2006.12.027>.
- 612 [58] Ferrero S, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V. Letrozole
613 combined with norethisterone acetate compared with norethisterone acetate alone in the
614 treatment of pain symptoms caused by endometriosis. *Hum Reprod* 2009;24:3033–41.

- 615 <https://doi.org/10.1093/humrep/dep302>.
- 616 [59] Vercellini P, Barbara G, Somigliana E, Ph D, Bianchi S, Abbiati A, et al. Comparison of
617 contraceptive ring and patch for the treatment of symptomatic endometriosis. *Fertil Steril*
618 2010;93:2150–61. <https://doi.org/10.1016/j.fertnstert.2009.01.071>.
- 619 [60] Ferrero S, Tramalloni D, Venturini PL, Remorgida V. Vaginal danazol for women with
620 rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-
621 releasing intrauterine device. *Int J Gynecol Obstet* 2011;113:116–9.
622 <https://doi.org/10.1016/j.ijgo.2010.11.015>.
- 623 [61] Ferrero S, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate
624 versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: A
625 randomized controlled trial. *Reprod Biol Endocrinol* 2011;9:88.
626 <https://doi.org/10.1186/1477-7827-9-88>.
- 627 [62] Mabrouk M, Solfrini S, Frascà C, Del Forno S, Montanari G, Ferrini G, et al. A new oral
628 contraceptive regimen for endometriosis management: Preliminary experience with 24/4-day
629 drospirenone/ethinilestradiol 3mg/20 mcg. *Gynecol Endocrinol* 2012;28:451–4.
630 <https://doi.org/10.3109/09513590.2011.634936>.
- 631 [63] Vercellini P, Somigliana E, Consonni D, Frattaruolo MP, Giorgi O De, Fedele L. Surgical
632 versus medical treatment for endometriosis-associated severe deep dyspareunia : I . Effect on
633 pain during intercourse and patient satisfaction. *Hum Reprod* 2012;27:3450–9.
634 <https://doi.org/10.1093/humrep/des313>.
- 635 [64] Leone U, Maggiore R, Remorgida V, Scala C, Venturini PL, Ferrero S. Desogestrel-only
636 contraceptive pill versus sequential contraceptive vaginal ring in the treatment of
637 rectovaginal endometriosis infiltrating the rectum : a prospective open-label comparative
638 study. *Acta Obstet Gynecol Scand* 2014;93:239–47. <https://doi.org/10.1111/aogs.12326>.
- 639 [65] Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestogen-only contraceptive pill
640 compared with combined oral contraceptive in the treatment of pain symptoms caused by

- 641 endometriosis in patients with migraine without aura. *Eur J Obstet Gynecol Reprod Biol*
642 2014;179:63–8. <https://doi.org/10.1016/j.ejogrb.2014.05.016>.
- 643 [66] Morotti M, Sozzi F, Remorgida V, Venturini PL, Ferrero S. Dienogest in women with
644 persistent endometriosis-related pelvic pain during norethisterone acetate treatment. *Eur J*
645 *Obstet Gynecol Reprod Biol* 2014;183:188–92. <https://doi.org/10.1016/j.ejogrb.2014.10.036>.
- 646 [67] Roman H, Saint Ghislain M, Milles M, Marty N, Hennetier C, Moatassim S, et al.
647 Improvement of digestive complaints in women with severe colorectal endometriosis
648 benefiting from continuous amenorrhoea triggered by triptorelin. A prospective pilot study.
649 *Gynecol Obstet Fertil* 2015;43:575–81. <https://doi.org/10.1016/j.gyobfe.2015.07.001>.
- 650 [68] Yela DA, Kajikawa P, Donati L, Cursino K, Giraldo H, Benetti-pinto CL. Deep infiltrating
651 endometriosis treatment with dienogest: a pilot study. *J Endometr Pelvic Pain Disord*
652 2015;7:33–7. <https://doi.org/10.5301/je.5000202>.
- 653 [69] Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating
654 endometriosis: The remission of symptoms is not related to endometriosis nodule remission.
655 *Eur J Obstet Gynecol Reprod Biol* 2017;211:108–11.
656 <https://doi.org/10.1016/j.ejogrb.2017.02.015>.
- 657 [70] Morotti M, Venturini PL, Biscaldi E, Racca A, Calanni L, Vellone VG, et al. Efficacy and
658 acceptability of long-term norethindrone acetate for the treatment of rectovaginal
659 endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2017;213:4–10.
660 <https://doi.org/10.1016/j.ejogrb.2017.03.033>.
- 661 [71] Scala C, Leone Roberti Maggiore U, Barra F, Venturini PL, Ferrero S. Norethindrone acetate
662 versus extended-cycle oral contraceptive (Seasonique ®) in the treatment of endometriosis
663 symptoms: A prospective open-label comparative study. *Eur J Obstet Gynecol Reprod Biol*
664 2018;222:89–94. <https://doi.org/10.1016/j.ejogrb.2018.01.022>.
- 665 [72] Leonardo-pinto JP, Benetti-pinto CL. When solving dyspareunia is not enough to restore
666 sexual function in women with deep infiltrating endometriosis treated with dienogest. *J Sex*

- 667 Marital Ther 2018;0715. <https://doi.org/10.1080/0092623X.2018.1474411>.
- 668 [73] Ferrero S, Scala C, Ciccarelli S, Vellone VG, Ferrero S, Scala C, et al. Treatment of
669 rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant. *Gynecol*
670 *Endocrinol* 2019;0:1–5. <https://doi.org/10.1080/09513590.2019.1689552>.
- 671 [74] Ferrero S, Camerini G, Ragni N, Menada MV, Venturini PL, Remorgida V. Triptorelin
672 improves intestinal symptoms among patients with colorectal endometriosis. *Int J Gynecol*
673 *Obstet* 2010;108:250–1. <https://doi.org/10.1016/j.ijgo.2009.09.028>.
- 674 [75] Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Remorgida V. Norethisterone
675 acetate in the treatment of colorectal endometriosis : a pilot study. *Hum Reprod* 2010;25:94–
676 100. <https://doi.org/10.1093/humrep/dep361>.
- 677 [76] Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Seracchioli R, et al. Letrozole and
678 norethisterone acetate in colorectal endometriosis. *Eur J Obstet Gynecol Reprod Biol*
679 2010;150:199–202. <https://doi.org/10.1016/j.ejogrb.2010.02.023>.
- 680 [77] Harada M, Osuga Y, Izumi G, Takamura M, Takemura Y, Hirata T, et al. Dienogest, a new
681 conservative strategy for extragenital endometriosis: A pilot study. *Gynecol Endocrinol*
682 2011;27:717–20. <https://doi.org/10.3109/09513590.2010.533800>.
- 683 [78] Ferrari S, Persico P, Di Puppò F, Viganò P, Tandoi I, Garavaglia E, et al. Continuous low-
684 dose oral contraceptive in the treatment of colorectal endometriosis evaluated by rectal
685 endoscopic ultrasonography. *Acta Obstet Gynecol Scand* 2012;91:699–703.
686 <https://doi.org/10.1111/j.1600-0412.2012.01366.x>.

687

688

Table 1. Effect of aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRHa), oestrogen-progestins, and progestins as assessed in studies on the treatment of rectovaginal endometriosis (literature data, 2000-2020).

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
Fedele <i>et al.</i> , 2000 [52]	Prospective	15	Leuprolide acetate 3.75 mg IM/28 day	6 months	NR	Improvement of pain symptoms during treatment. High rate of pain recurrence after drug discontinuation. Transient regression of nodule size during treatment with return to baseline volume during follow-up.
Fedele <i>et al.</i> , 2001 [53]	Prospective	11	LNG-IUD	12 months	Headache (37) Breast tenderness (37) Weight gain >1 kg (37) Seborrhoea, oily hair, acne (27)	Significant improvement of dysm and CPP. Partial amelioration of deep dysp. Significant reduction of nodule size after 6 months of treatment. At the end of treatment period 9 patients were oligomenorrhic and 2 experienced amenorrhea.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
Vercellini <i>et al.</i> , 2005 [54]	RCT	90	Continuous low-dose monophasic OC (EE 0.01 plus cyproterone acetate 3 mg)/day (<i>n</i> = 45) (VS NETA 2.5 mg/day per os) (<i>n</i> = 45)	12 months	Group OC: Weight gain (16) Headache (7) Nausea (7) Depression (4) Decreased libido (4) Acne (2) Bloating (2) Breast tenderness (2) Hypertriglyceridemia (2) Group NETA: Weight gain (27) Decreased libido (9) Bloating (9) Depression (7) Headache (4) Acne (4)	Similar pain relief and dropout rates. Higher satisfaction with treatment in NETA group.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Erythematous cutaneous reaction (2)	
Hefler <i>et al.</i> , 2005 [55]	Prospective	10	Vaginal anastrozole 0.25 mg/day	6 months	No severe adverse events reported during study period	Significant improvement of dysm and QoL. CPP and dysp remained unchanged during treatment. No significant changes in BMD and nodule volume size during treatment.
Razzi <i>et al.</i> , 2007 [56]	Prospective	21	Vaginal danazol 200 mg/day	12 months	Vaginal irritation (19)	Significant improvement of dysm, dysp, and CPP. Significant reduction of nodule size after 6-months of treatment. No significant change of serum metabolic and thrombophilic parameters.
Remorgida <i>et al.</i> , 2007 [57]	Prospective	12	Letrozole 2.5 mg/day plus NETA 2.5/day per os	6 months	Weight gain (33) Mood swings (33) Weakness (25) Bone and joint pain (25)	Significant pain relief and QoL improvement during treatment. At 6-months' follow-up recurrence of pain symptoms and worsening of QoL

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Vaginal spotting (17) Muscle aches (17) Headache (17) Depression (17) Hot flushes (8) Nausea (8) Decreased libido (8)	scores in all patients. No BMD changes during treatment.
Ferrero <i>et al.</i> , 2009 [58]	PPT	82	Letrozole 2.5 mg plus NETA 2.5 mg/day per os (<i>n</i> = 41) (VS NETA 2.5 mg/day per os) (<i>n</i> = 41)	6 months	Group Letrozole plus NETA: Weight gain (20) Joint pain (17) Myalgia (12) Spotting (10) Breakthrough bleeding (5) Migraine (5) Myalgia (2)	Greater pain relief with letrozole plus NETA, but fewer side effects and higher patient satisfaction rate with NETA only. Similar pain at follow- up. No BMD changes during treatment.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Depression (2) Hair loss (2) Decreased libido (2) Group NETA: Weight gain (17) Breakthrough bleeding (7) Spotting (7) Migraine (7) Depression (2)	
Vercellini <i>et al.</i> , 2010 [59]	PPT	59 ^a	Vaginal ring (EE 15 µg plus etonogestrel 120 µg) (<i>n</i> = 38) (VS transdermal patch - EE 20 µg plus	12 months	Group vaginal ring: Bloating (10) Vaginal discomfort (7) Depression (6) Weight gain (6) Headache (6) Breast tenderness (5)	Greater pain relief and satisfaction with vaginal ring.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
			norelgestromin 150 µg) (<i>n</i> = 21)		Decreased libido (4) Nausea (2) Group patch: Headache (18) Nausea (8) Breast tenderness (8) Weight gain (5) Depression (5) Decreased libido (5) Cutaneous reaction (5) Bloating (3) Vaginal dryness (2) Vomiting (2)	
Ferrero <i>et al.</i> , 2011 [60]	Observational pilot study ^b	15	Vaginal danazol 100 mg/day	6 months	Seborrhea, oily hair, acne (27) Headache (20)	Significant improvement of dysm, dysp, CPP, and dyschezia and reduction of nodule size after 6 months of treatment. High

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Weight gain >3 kg (13) Vaginal irritation (13)	satisfaction rate with the treatment (80% of women were satisfied or very satisfied).
Ferrero <i>et al.</i> , 2011 [61]	RCT	35	Letrozole 2.5 mg plus NETA 2.5 mg/day per os (<i>n</i> = 17) (VS letrozole 2.5 mg/day per os plus triptorelin 11.25 mg/3 months IM) (<i>n</i> = 18)	6 months	NETA group: Weight gain (12) Decreased libido (12) Spotting (12) Myalgia and arthralgia (12) Depression (6) Triptorelin group: Myalgia and arthralgia (56) Decreased libido (22) Depression (22) Hot flushes (22) Vaginal dryness (17)	Similar pain relief. Higher patient satisfaction with treatment in NETA group. Higher discontinuation rates in the triptorelin group. Greater nodule size reduction with triptorelin. Significant reduction of BMD in women treated with triptorelin.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Insomnia (17) Hair loss (11) Headache (11) Weight gain (6)	
Mabrouk <i>et al.</i> , 2012 [62]	Retrospective	106	Cyclic low-dose monophasic OC (EE 20 µg plus drospirenone 3 mg)/day (<i>n</i> = 75) (VS no treatment) (<i>n</i> = 31)	5.8 (3.7) months ^c	NR	No significant variations in pain scores and nodule size in OC group. Significant worsening of dysm and deep dysp scores, and enlargement of nodule size in nonuser group. No significant changes in QoL scores during study period nor between groups.
Vercellini <i>et al.</i> , 2012 [63]	PPT	59 ^a	NETA 2.5 mg/day per os (<i>n</i> = 35)	12 months	Weight gain (34) Breakthrough bleeding (20) Decreased libido (19) Vaginal dryness (12)	At the end of follow-up comparable satisfaction and improvement of deep dysp.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
			(VS second-line laparoscopic excision of endometriotic lesions) (<i>n</i> = 24)		Spotting (11) Breast tenderness (6) Bloating (5) Headache (4) Depression (4) Nausea (2)	
Leone Roberti Maggiore <i>et al.</i> , 2014 [64]	PPT	143	DSG 75 µg/day per os (<i>n</i> = 60) (VS vaginal ring - EE 15 µg plus etonogestrel 120 µg) (<i>n</i> = 83)	12 months	Group DSG: Breakthrough bleeding (8) Metrorrhagia (2) Weight gain (2) Group vaginal ring: Weight gain (6) Spotting (2)	Higher patient satisfaction with treatment in DSG group. Similar reduction in the volume of rectovaginal nodules. Comparable discontinuation rates.
Morotti <i>et al.</i> , 2014 [65]	PPT	144	DSG 75 µg/day per os (<i>n</i> = 62)	6 months	Group DSG: Bleeding (8)	Higher satisfaction with treatment in DSG group. Similar pain relief (dysp

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
			(VS cyclic low-dose monophasic OC - EE 20 µg plus DSG 150 µg/day) (<i>n</i> = 82)		Weight gain (2) Mood changes (2) Group OC: Increased migraine (11) Bleeding (6) Weight gain (2) Mood changes (1) Decreased libido (1) Acne (1) Peripheral edema (1)	and CPP). Lower rate of migraine attacks with DSG.
Morotti <i>et al.</i> , 2014 [66]	Open-label prospective study ^d	25	DNG 2 mg/day per os (<i>n</i> = 25)	6 months	Headache (16) Nausea (8) Breast tenderness (4)	Improvement of pain symptoms, sexual function, QoL and satisfaction with DNG.
Roman <i>et al.</i> , 2015 [67]	Prospective case series	70	Triptorelin acetate 11.25 mg IM depot injection	3.4 ± 1.8 months	--	Improvement of cyclic digestive complaints in more than half of patients. Constipation and non-cyclic

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
			plus percutaneous estradiol 0.1% /day			symptoms were improved in in less than a third of patients.
Yela <i>et al.</i> , 2015 [68]	Prospective	16	DNG 2 mg/day per os	6 months	Headache Acne Decreased libido Breast pain Hair loss Nausea/vomit Bloating Vaginal dryness	Significant improvement of pain symptoms (dysm, dysp, CPP, and dyschezia). No significant changes in volume size of endometriotic nodules. No significant changes in QoL and sexual function.
Vercellini <i>et al.</i> , 2016 [50]	Before-after study	60 ^a	DNG 2 mg/day per os (<i>n</i> = 29) (VS NETA 2.5 mg/day per os) (<i>n</i> = 31)	6 months	Group DNG: Weight gain (16) Spotting (13) Decreased libido (9) Vaginal dryness (7) Bloating (6)	Similar satisfaction with treatment and pain relief.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Alopecia (5) Headache (3) Mood disorders (2) Breast tenderness (1) Nausea (1) Breakthrough bleeding (1) Group NETA: Weight gain (31) Spotting (22) Decreased libido (14) Vaginal dryness (13) Mood disorders (8) Breast tenderness (8) Bloating (5) Acne (4)	

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Headache (3) Alopecia (1) Breakthrough bleeding (1)	
Leonardo-Pinto <i>et al.</i> , 2017 [69]	Prospective	30	DNG 2 mg/day per os	12 months	Headache (63) Breast pain (43) Decreased libido (43) Nausea/vomit (23)	Significant improvement of pain symptoms (dysm, dysp, CPP, bowel pain) and QoL. No significant changes in volume size of endometriotic nodules. No relation between remission of pain symptoms and reduction of the volume of endometriotic nodules.
Morotti <i>et al.</i> , 2017 [70]	Retrospective	103 (61 completed the 5 year follow-up)	NETA 2.5 mg/day per os [°]	5 years	Weight gain (30) Vaginal bleeding (23) Lipids alteration (12) Decreased libido (11)	Significant improvement of dysm, CPP, dyschezia and dysp. At the end of study period 69% of women were satisfied or very satisfied with the treatment, 40.8% of all patients in the

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Headache (9) Bloating (8) Depression (7) Acne (5) Erythematous cutaneous reaction (1)	intention to treat analysis (ITT). Significant reduction in the volume of the endometriotic nodules. At the end of study period, 11.9% of the patients displayed a volumetric increase of rectovaginal endometriosis.
Scala <i>et al.</i> , 2018 [71]	Patient preference study	100 (52 with rectovaginal endometriotic nodules)	NETA (2.5 mg/day) (VS Extended-cycle OC – LNG 150 mcg and EE 30 mcg for 84 days and EE 10 mcg for 7 days)	12 months	Unscheduled bleeding Spotting	No significant difference in the rate of satisfied patients at 12-month follow up between the two study groups. At 6-month and 12-month follow up, significant amelioration in the intensity of all pain symptoms compared with baseline in both groups. Significant within group reduction of rectovaginal endometriotic nodules

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
						volumes, without between groups differences.
Leonardo-Pinto <i>et al.</i> , 2018 [72]	Prospective	30	DNG 2mg/die	12 months	Headache (63) Decrease in desire (43) Nausea (23)	Significant improvement of dysm, CPP and dysp. Significant improvement in sexual function (assessed with FSFI), but no significant enhancement in desire, lubrication and satisfaction domains of FSFI. Sexual function was not completely restored.
Ferrero <i>et al.</i> , 2019 [73]	Retrospective	44	Etonogestrel-releasing implant	24 months	Headache (23) Dizziness (14) Acne (7)	Significant improvement of dysm, CPP, dyschezia and deep dysp. Significant improvement in all domains of the EHP-30

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
						questionnaire. Significant reduction in endometriotic nodules volume.

^a Only the sub-group of patients with rectovaginal endometriosis was considered.

^b Only patients with symptomatic rectovaginal endometriosis who had pain persistence after insertion of a LNG-IUD were selected.

^c Mean (SD).

^d Only patients with symptomatic rectovaginal endometriosis who had pain persistence and were unsatisfied after 6-months of treatment with NETA were selected.

^e In case of breakthrough bleeding the dose of NETA was increased from 2.5 to 5 mg/day.

BMD = bone mineral density; CPP = chronic pelvic pain; DNG = dienogest; DSG = desogestrel; dysm = dysmenorrhoea; dysp = dyspareunia; EE = ethinyl estradiol; EHP = endometriosis health profile; FSFI = female sexual function index; IUD = intrauterine device; IM = intramuscular; LNG = levonorgestrel; NETA = nor-ethisterone acetate; NR = not reported; OC = oral contraceptive; PPT = patient-preference trial; QoL = quality of life; RCT = randomized controlled trial; VAS = visual analogue scale.

Table 2. Effect of aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRHa), oestrogen-progestogens, and progestogens as assessed in studies on the treatment of proximal rectum and rectosigmoid junction endometriosis (literature data, 2000–2020) ^a

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
Ferrero <i>et al.</i> , 2010 [74]	Prospective case series	18	Triptorelin 11.25 mg/3 months IM plus tibolone 2.5 mg/day per os	12 months	Hot flushes (33) Vaginal bleeding (33) Sweating episodes 3(17) Vaginal dryness and superficial dyspareunia (11) Nervousness and irritability (11) Weight gain (11) Sleeplessness (6) Fatigue (6) Difficulty in concentration (6)	Significant improvement of pain symptoms. Improvement in intestinal function in patients with symptoms mimicking IBS-D. At 12-month assessment 13 (72%) women were very satisfied or satisfied, 2 (11%) were uncertain, and 3 (17%) were dissatisfied.
Ferrero <i>et al.</i> , 2010 [75]	Prospective case series	40	NETA 2.5 mg/day per os ^b	12 months	Worsening of constipation (7.5) Breakthrough bleeding (5)	Significant improvement of dysm, dysp, CPP, dyschezia and diarrhea. No significant improvement in

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Weight gain (5) Spotting (2.5) Depression (2.5) Migraine attacks (2.5)	patients with constipation, abdominal bloating and feeling of incomplete evacuation after bowel movements. 60% of patients were satisfied or very satisfied with the treatment.
Ferrero <i>et al.</i> , 2010 [76]	Prospective case series	6	Letrozole 2.5 mg/day plus NETA 2.5 mg/day per os	6 months	Breakthrough bleeding (17) Weight gain (17) Joint pain (17) Decreased libido (17)	Significant improvement of dysm, dysp, CPP, and gastrointestinal symptoms. High satisfaction rate at the end of study period (67% of women were satisfied or very satisfied). No changes in BMD were identified.
Harada <i>et al.</i> , 2011 [77]	Retrospective case series	4	DNG 2 mg/day per os	12 months	Spotting (75) Hot Flushes (50) Gastralgia (25) Depression (25)	Significant improvement of pain symptoms and reduction in nodule size.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
Ferrari <i>et al.</i> , 2012 [78]	Prospective case series	26	Continuous low-dose monophasic OC (EE 15 µg plus gestodene 60 µg)/day	12 months	Breakthrough bleeding (38) Weight gain (23) Headache (12) Decreased libido (8)	Significant improvement of dysm, dysp, CPP, and dyschezia. Significant reduction of nodule size after 12 months of treatment. High satisfaction rate at the end of study period (69% of women were satisfied or very satisfied).
Vercellini <i>et al.</i> , 2018 [20]	Retrospective cohort study	50 ^c	Continuous low-dose monophasic OC (EE 15 µg plus gestodene 60 µg)/day; NETA 2.5 mg/day per os; DNG 2 mg/day per os	40 (18-60) months	Weight gain (32) Decreased libido (18) Bloating (16) Vaginal dryness (16) Headache (10) Mood changes (4)	At final follow-up, 14 patients were very satisfied, 22 satisfied, 5 neither satisfied nor dissatisfied, 7 dissatisfied, and 2 very dissatisfied. Significant improvements of bowel symptoms as assessed by both the Knowles-Eccersley-Scott-Symptom Questionnaire (KESS) and the numerical rating scale.

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
Andres <i>et al.</i> , 2019 [34]	Retrospective cohort study	238	Oral progestogens, OCs, medroxyprogesterone acetate IM depot injection, LNG-IUD, GnRH analogues	6 months	Complications in the clinical group: intestinal partial obstruction requiring urgent surgery (0.6).	<p>After 6 months, 60% patients reported improvement in pain symptoms, while 39.9% were referred for surgical treatment due to worsening or persistence of pain symptoms (28.6%), growth of endometriosis lesions (10.9%) or symptoms of bowel su-occlusion (0.4%).</p> <p>Significant reduction of dysm, dysp, CPP, dysuria and dyschezia in both medical and surgical treatment alike.</p> <p>Greater reduction in dyschezia and CPP in the medical group.</p> <p>Greater reduction of dyspareunia in the surgical group. Higher major</p>

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
						complications rates in the surgical group.
Egekvist <i>et al.</i> , 2019 [29]	Prospective study	80	OCs, oral progestogens, LNG-IUD, GnRH analogues with oestrogen-progestogen add-back	12 months	NR	Significant improvement of dysmenorrhea. No significant improvement in CPP and dyschezia. Quality of life scores (SF-36 and EHP-30) were comparable to normative data for Danish women of similar age and did not change with time. No significant changes in volume of endometriotic nodules. No association between change in size of the rectosigmoid nodule and change in symptoms.
Netter <i>et al.</i> , 2019 [32]	Retrospective	43	Continuous OCs, oral progestogens and GnRH analogues	38.3 months (mean)	NR	About 60.5% of patients demonstrated stability of their colorectal lesions between the two

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
			(VS no amenorrhoea or pregnancy)			MRIs, 27.9% of patients had a progression of lesions and 11.6% had a regression of lesions. Median duration of amenorrhoea was significantly lower in women with progression of lesions. Progression of rectosigmoid nodules was observed in 34% of patients without continuous amenorrhoea, in 39% who had never had amenorrhoea and in no patients with continuous amenorrhoea.
Barra <i>et al.</i> , 2020 [33]	Retrospective	83	DNG 2mg/die	6 - 36 months	Weight gain (30) Abnormal uterine bleeding (27) Headache (21) Depression (10)	Significant improvement of pain (dysm, dysp, CPP, dysuria and dyschezia) and intestinal symptoms. Progressive increase of the Endometriosis Health Profile-30

Source	Study design	Patients enrolled (<i>n</i>)	Study drug (comparator)	Treatment period	Adverse effects (%)	Outcome
					Decreased libido (4) Acne (2)	(EHP-30) and Gastrointestinal Quality of Life Index (GIQLI) scores was observed in the first two years of therapy. Significant reduction of endometriotic nodules volume.

^a Egekvist *et al.* [29] was not included because the exact number of patients who used different medical treatments (oral oestrogen-progestogens, progestogens, or LNG-IUD), the adverse effects associated with their use, and the precise pain symptoms or gastrointestinal symptoms variation could not be extracted from the published report.

^b In case of breakthrough bleeding the daily oral dose of NETA was doubled.

^c Only patients who chose medical treatment are here reported.

BMD = bone mineral density; CPP = chronic pelvic pain; DNG = dienogest; dysm = dysmenorrhea; dysp = dyspareunia; EE = ethinyl-estradiol; GnRH = gonadotropin-releasing hormone; IBS-D = diarrhoea-predominant irritable bowel syndrome; IM = intramuscular; IUD = intrauterine device; LNG = levonorgestrel; MRI = magnetic resonance imaging; NETA = nor-ethisterone acetate; NA = not applicable; NR = not reported; OC = oral contraceptive; SF-36 = Short Form 36.